Eagle Pharmaceuticals

Eagle Pharmaceuticals

NJ - Woodcliff Lake
Pharmaceutical
WebsiteLinkedInCareers Page

Focus: Repurposing Existing Drugs

Eagle Pharmaceuticals is a life sciences company focused on Repurposing Existing Drugs.

Neurology
Funding Stage
PUBLIC
Open Jobs
0

Products & Portfolio (5)

BELRAPZO
bendamustine hydrochloride
Peak
INTRAVENOUS · SOLUTION
purine-like benzimidazole ring. Mechlorethamine and its derivatives form electrophilic alkyl groups. These groups form covalent bonds with electron-rich nucleophilic moieties, resulting in interstrand DNA crosslinks. The bifunctional covalent linkage can lead to cell death via several pathways. Bendamustine is active against both quiescent and dividing cells. The exact mechanism of action of bendamustine remains unknown.
within six months of treatment with rituximaba rituximab-containing regimenleukemia+1 more
2018
0
BENDEKA
bendamustine hydrochloride
Peak
INTRAVENOUS · SOLUTION
purine-like benzimidazole ring. Mechlorethamine and its derivatives form electrophilic alkyl groups. These groups form covalent bonds with electron-rich nucleophilic moieties, resulting in interstrand DNA crosslinks. The bifunctional covalent linkage can lead to cell death via several pathways. Bendamustine is active against both quiescent and dividing cells. The exact mechanism of action of bendamustine remains unknown.
within six months of treatment with rituximaba rituximab-containing regimenleukemia+1 more
2015
0
PEMFEXY
pemetrexed
Peak
INTRAVENOUS · SOLUTION
folate-dependent metabolic processes essential for cell replication. In vitro studies show that pemetrexed inhibits thymidylate synthase (TS), dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT), which are folate-dependent enzymes involved in the de novo biosynthesis of thymidine and purine nucleotides. Pemetrexed is taken into cells by membrane carriers, such as the reduced folate carrier and membrane folate binding protein transport systems. Once in the cell, pemetrexed is converted to polyglutamate forms by the enzyme folylpolyglutamate synthetase. The polyglutamate forms are retained in cells and are inhibitors of TS and GARFT.
combination with cisplatin for the initial treatment of patients with malignant pleural mesothelioma whose disease is unresectablelung cancer
2020
0
RYANODEX
dantrolene sodium
Peak
INTRAVENOUS · FOR SUSPENSION
2014
30
VASOPRESSIN
vasopressin
Post-LOE
INTRAVENOUS · SOLUTION
2021
30

Pipeline & Clinical Trials

Liquefied petroleum gas
Infant, Low Birth Weight
N/A
Clinical Trials (1)
NCT02944682Household Air Pollution and Health: A Multi-country LPG Intervention Trial
N/A
Amphotericin B Liposome for Injection
Invasive Fungal Infections
N/A
Clinical Trials (1)
NCT06977490Human Bioequivalence Study of Amphotericin B Liposome for Injection
N/A
i-STAT Alinity TBI test
TBI (Traumatic Brain Injury)
N/A
Clinical Trials (1)
NCT07373509Emergency Department Implementation of the i-STAT Alinity Traumatic Brain Injury Whole Blood Test
N/A
Fulvestrant for Injectable Suspension
Pharmacokinetics
Phase 1
Clinical Trials (1)
NCT03324061Study to Evaluate the Safety, Tolerability, and PK of Fulvestrant After IM Administration
Phase 1
Phase 1
Clinical Trials (1)
NCT02162888A Phase I, Bioequivalence Study to Evaluate Two Formulations of Bendamustine (BDM) Hydrochloride (HCl) Administered to Cancer Patients
Phase 1
Dantrolene sodium for injectable suspension
Heat Stroke
Phase 2
Clinical Trials (1)
NCT02513095Efficacy and Safety of Ryanodex® (EGL-4104) as Adjuvant Treatment in Subjects With Exertional Heat Stroke (EHS)
Phase 2
Phase 2
Clinical Trials (1)
NCT05776004Blinded Efficacy and Safety Study of CAL02 IV Plus SOC in Subjects With Severe Community-Acquired Bacterial Pneumonia
Phase 2
Phase 2
Clinical Trials (1)
NCT00933348Safety and Efficacy of the Fruit-based Product OPAL A for the Treatment of Chronic Venous and Pressure Ulcers
Phase 2
Phase 2
Clinical Trials (1)
NCT03189433Efficacy and Safety Study of Ryanodex as Adjuvant Treatment in Subjects With Psychostimulant Drug-Induced Toxicity (PDIT)
Phase 2
Phase 2
Clinical Trials (1)
NCT00881075Safety and Efficacy of SeeMore (TM) in Heart Patients
Phase 2
Phase 3
Clinical Trials (1)
NCT01045018A BE Study Comparing Mesalamine 400 mg to ASACOL® 400 mg in Patients With Mild To Moderately Active Ulcerative Colitis
Phase 3
Ryanodex and Standard of Care
Exertional Heat Stroke
Phase 3
Clinical Trials (1)
NCT03600376Study to Assess the Efficacy and Safety of Ryanodex as Adjuvant Treatment in Subjects With EHS
Phase 3
Arm 1 Cataract Surgery performed with remimazolam as sedative
Cataract Surgery Anesthesia
Phase 4
Clinical Trials (1)
NCT07325227Study of Remimazolam for Cataract Surgery
Phase 4

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts
Founded: 2023
Portfolio: 5 approved products, 13 clinical trials
Top TAs: Oncology
Portfolio Health
Peak4 (80%)
Post-LOE1 (20%)
5 total products
Therapeutic Area Focus
Oncology
3 marketed
Marketed
Pipeline

Hiring Trend

Stable
0
Open Roles
+0
Added
-0
Filled/Removed

Based on last 3 crawl cycles